PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials

“With combination therapy at the forefront of innovative cancer treatment, we will see its application earlier in the clinical process. It’ll require some creativity and robust statistical models to validate the approach, but we will likely see combination therapies in more phase 1 trials within a dose escalation model. This approach can potentially save invaluable time for patients through an alternative development timeline, especially when a drug is designed specifically for combination treatment. It’s already become a reality for a small number of trials — specifically within oncology — but it has the potential to expand to more oncology trials in 2025.”

Francis Burrows, Ph.D.
Kura Oncology’s Chief Scientific Officer